We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Immunological Tests Detects Schistosomiasis in Low-Endemicity Area

By LabMedica International staff writers
Posted on 02 Apr 2014
The prevalence of Schistosoma mansoni infection has been systematically determined using the indirect immunofluorescence assay-immunoglobulin M (IFA-IgM) and circumoval precipitin test (COPT) techniques with serum samples.

Schistosomiasis is a major public health problem, with an estimated 200 million people infected worldwide and as a consequence of effective schistosomiasis control programs based on mass or selective chemotherapy, basic sanitation measures, and use of molluscicides, the prevalence of human schistosomiasis has decreased considerably.

Parasitologists from the University of São Paulo (Brazil) conducted a cross-sectional study was from April to December 2011 in several districts on the outskirts of Barra Mansa, Rio de Janeiro, Brazil and collected 572 randomized feces and serum samples. More...
The majority of subjects in the study population were females. The average age of the population was 40 to 41 years old.

Fecal samples were processed and evaluated using the qualitative-quantitative Helm Test Kit (KK-HH, Biomanguinhos Fiocruz; Rio de Janeiro, Brazil). The COPT was used to detect antibody reactions against excretion and secretion products of S. mansoni eggs using previously described techniques. The IFA-IgM reading was performed using an Olympus BX-FLA fluorescence microscope (Olympus Corporation, Tokyo, Japan) equipped with an epi-illumination system.

The IFA-IgM identified the greatest number of S. mansoni infections (91/572, 15.9%), followed by COPT (29/572, 5.1%). The Helm test kit parasitological techniques identified the fewest infections (5/572, 0.9%). The COPT positivity showed a statistically significant difference compared with parasitological techniques. The level of agreement between COPT and parasitological techniques was higher than that with IFA-IgM. The higher COPT positivity compared with parasitological techniques may be caused by oviposition occurrence, where eggs deposited in the deepest layers of the intestine can be detected even in the absence of eggs in feces, especially in chronic infections in patients over 40 years of age and with low parasite load.

The authors concluded that positivity rates were highest using IFA-IgM compared with parasitological techniques and COPT. Therefore, it could be used as a primary approach to screen a large number of suspected cases of schistosomal infection in epidemiological studies, in combination with the KK-HH techniques and confirmation of IFA-IgM-positive cases with COPT techniques would be beneficial in low-endemicity areas. The study was published on March 17, 2014, in the American Journal of Tropical Medicine and Hygiene.

Related Links:
University of São Paulo
Biomanguinhos
Olympus Corporation



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Automated Cell Culture Chemistry Analyzer
BioProfile FLEX2 Basic
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.